Evaxion Biotech A/S (EVAX) Stock Price, News & Analysis

Company Overview

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.

Key Stats

• Today's Range: $2.67 to $2.84
• 50-Day Range: $1.31 to $2.74
• 52-Week Range: $1.20 to $19.95
• Volume: 31,420 shs
• Average Volume: 608,202 shs
• Market Capitalization: $3.80 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.00
• Consensus Rating: Buy

Evaxion Biotech A/S Stock Analysis - MarketRank™

Evaxion Biotech A/S scored higher than 59% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Evaxion Biotech A/S has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Evaxion Biotech A/S has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Evaxion Biotech A/S are expected to decrease in the coming year, from ($0.15) to ($0.67) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Evaxion Biotech A/S is -1.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Evaxion Biotech A/S is -1.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.07% of the float of Evaxion Biotech A/S has been sold short.

Short Interest Ratio / Days to Cover

Evaxion Biotech A/S has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Evaxion Biotech A/S has recently decreased by 34.95%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Evaxion Biotech A/S does not currently pay a dividend.

Dividend Growth

Evaxion Biotech A/S does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.07% of the float of Evaxion Biotech A/S has been sold short.

Short Interest Ratio / Days to Cover

Evaxion Biotech A/S has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Evaxion Biotech A/S has recently decreased by 34.95%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.36

News Sentiment

Evaxion Biotech A/S has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.86 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for Evaxion Biotech A/S this week, compared to 2 articles on an average week.

Search Interest

5 people have searched for EVAX on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.

MarketBeat Follows

1 people have added Evaxion Biotech A/S to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Evaxion Biotech A/S insiders have not sold or bought any company stock.

Percentage Held by Insiders

41.64% of the stock of Evaxion Biotech A/S is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 11.04% of the stock of Evaxion Biotech A/S is held by institutions.

EVAX Stock Analysis - Frequently Asked Questions

How have EVAX shares performed this year?

Evaxion Biotech A/S's stock was trading at $4.2270 at the beginning of the year. Since then, EVAX shares have decreased by 34.4% and is now trading at $2.7710.
View the best growth stocks for 2025 here.

How were Evaxion Biotech A/S's earnings last quarter?

Evaxion Biotech A/S (NASDAQ:EVAX) released its earnings results on Tuesday, May, 27th. The company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.65) by $0.36.
Read the conference call transcript.

When did Evaxion Biotech A/S's stock split?

Evaxion Biotech A/S shares reverse split before market open on Monday, January 13th 2025. The 1-5 reverse split was announced on Monday, December 30th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 10th 2025. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

When did Evaxion Biotech A/S IPO?

Evaxion Biotech A/S (EVAX) raised $31 million in an initial public offering on Friday, February 5th 2021. The company issued 2,800,000 shares at a price of $10.00-$12.00 per share. Oppenheimer & Co. acted as the underwriter for the IPO and Ladenburg Thalmann was co-manager.

Who are Evaxion Biotech A/S's major shareholders?

Evaxion Biotech A/S's top institutional investors include Merck & Co. Inc. (86.54%) and XTX Topco Ltd (1.16%).

How do I buy shares of Evaxion Biotech A/S?

Shares of EVAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Evaxion Biotech A/S own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Evaxion Biotech A/S investors own include PayPal (PYPL), Arista Networks (ANET), Tesla (TSLA), ChargePoint (CHPT), MercadoLibre (MELI), ASML (ASML).

Company Calendar

• Last Earnings: 5/27/2025
• Today: 6/04/2025
• Next Earnings (Estimated): 8/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:EVAX
• CIK: 1828253
• Web: www.evaxion-biotech.com
• Phone: 45-5353-1850
• Fax: N/A
• Employees: 60
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $10.00
• High Stock Price Target: $14.00
• Low Stock Price Target: $6.00
• Potential Upside/Downside: +260.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.16)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$22.12 million
• Net Margins: -347.83%
• Pretax Margin: -368.80%
• Return on Equity: N/A
• Return on Assets: -79.40%

Debt

• Debt-to-Equity Ratio: 7.99
• Current Ratio: 1.00
• Quick Ratio: 2.80

Sales & Book Value

• Annual Sales: $3.29 million
• Price / Sales: 1.18
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($5.83) per share
• Price / Book: -0.48

Miscellaneous

• Outstanding Shares: 1,403,000
• Free Float: 685,000
• Market Cap: $3.89 million
• Optionable: No Data
• Beta: -0.24